4.6 Article

Uncoupling the BMP receptor antagonist function from the WNT agonist function of R-spondin 2 using the inhibitory peptide dendrimer RWd

期刊

JOURNAL OF BIOLOGICAL CHEMISTRY
卷 298, 期 2, 页码 -

出版社

ELSEVIER
DOI: 10.1016/j.jbc.2022.101586

关键词

-

资金

  1. Deutsche Forschungsgemeinschaft (German Research Foundation) [SFB1324-B01]

向作者/读者索取更多资源

Bone morphogenetic proteins (BMPs) play important roles in various biological processes, including embryogenesis and disease. Recent studies have found that R-spondin 2 (RSPO2) acts as a BMP receptor antagonist, and a peptide derived from RSPO2 can uncouple BMP antagonist function from WNT agonist function, showing potential for therapeutic development in diseases like acute myeloid leukemia (AML). By using a dendrimer based on this peptide, it is possible to selectively target BMP receptor signaling, reduce cell growth, and induce differentiation in AML cells, as well as modulate embryonic patterning in Xenopus embryos.
Signaling by bone morphogenetic proteins (BMPs) plays pivotal roles in embryogenesis, adult tissue homeostasis, and disease. Recent studies revealed that the well-established WNT agonist R-spondin 2 (RSPO2) is also a BMP receptor (BMP receptor type 1A) antagonist, with roles in early Xenopus embryogenesis and human acute myeloid leukemia (AML). To uncouple the BMP antagonist function from the WNT agonist function and to promote development of AML therapeutics, here we identified a 10-mer peptide (RW) derived from the thrombospondin 1 domain of RSPO2, which specifically prevents binding between RSPO2 and BMP receptor type 1A without altering WNT signaling. We also show that a corresponding RW dendrimer (RWd) exhibiting improved half-life relieves inhibition of BMP receptor signaling by RSPO2 in human AML cells, reduces cell growth, and induces differentiation. Moreover, microinjection of RWd in Xenopus embryos ventralizes the dorsoventral embryonic patterning by upregulating BMP signaling without affecting WNT signaling. Our study corroborates the function of RSPO2 as a BMP receptor antagonist and provides a proof of concept for pharmacologically uncoupling BMP antagonist from WNT agonist functions of RSPO2 using the inhibitor peptide RWd with enhanced target selectivity and limited side effects.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据